Huge thanks to @Julia_Czs @pietznerm @BurulcaU @KopruluMine @KastenmullerLab @Julian_H0ffmann and many others! @QMULBartsTheLon @MRC_Epid @berlinnovation

We enable the community to query and visualise our results interactively through our webserver: https://t.co/BeXMlfkiyU

Our data can enhance interpretation of the ever-increasing number protein-disease associations. E.g. proteins associated with incident #PAD are enriched in those casually determined by #smoking status.

We performed #Mendelian randomization to identify major biological influences with putative causal effects on plasma protein levels.

#Proteins influenced by one or few strong factors can serve as biomarkers of health-related changes and exposures, e.g. #SOST for bone mass, #CTHRC1 for #lipid-lowering medications.

Liver and kidney function, inflammation and smoking status have wide-spread effects on the proteome (influencing >3k proteins). Anthropometric factors influenced a fewer number of proteins but had a stronger influence.

Joint genetic and biological factors explained >10% of variation for over a third of proteins. #Plasma proteins cluster into groups according to their major biological explanatory factor. Over a third of proteins were best explained by #modifiable factors.

#Proteomics capture thousands of plasma proteins. Most are not secreted, their origin and role are unclear. We characterised the joint contribution of >60 biological, #genetic and technical influences on 5k #plasma proteins in the Fenland study.

🚨🚨New paper alert 🚨🚨 https://t.co/FhzB0ehCuU https://t.co/A4zGRHLT8M

Want to get a summary of our paper and of the implications of our research? Check out our research briefing at @NatureMedicine https://t.co/GJf6VMOtcu

Amazing industry-academia collaboration with @Julia_Czs @pietznerm @jonathandavitte @profhhemingway @robert_a_scott and many others @GSK @QMULBartsTheLon @UCL_IHI @MRC_epid @Cambridge_Uni

We make our results available through our webserver ( https://t.co/qKjK9jhJ6q) to visualise the potential benefit of #proteomic screening in a Bayesian framework.

Severe diseases with poor prognosis among the best predicted: dilated cardiomyopathy, pulmonary fibrosis, #MultipleMyeloma , non-hodgkin lymphoma.

We find proteins predictive across more than 1 clinical specialty and specific disease predictors e.g. BCMA (TNFRSF17) for multiple myeloma, a target of multiple myeloma treatments.

For 52 diseases these performed better than standard clinical blood tests. e.g. those who will develop #MultipleMyeloma >6 times more likely to test with a high proteomic risk.

For 67 diseases, 5 to 20 proteins improved prediction over clinical risk factors up to 10 years before onset.

Precision medicine requires finding people at a high risk of disease. We used >3,000 proteins to develop sparse models for prediction of future risk of 218 diseases using #EHRs and #MachineLearning in @uk_biobank. https://t.co/N4QDqgUWwp https://t.co/YmBnZAENsO

https://t.co/HHisGxOdxu

We are so honoured for this recognition of our science. Go team!

Amazing collaboration with @SpirosDenaxas @pietznerm @_MatthiasArnold @KastenmullerLab @berlinnovation @QMULBartsTheLon @UCL_IHI